Semler Scientific (NASDAQ:SMLR) Given New $86.00 Price Target at Benchmark

Semler Scientific (NASDAQ:SMLR) had its target price trimmed by Benchmark from $101.00 to $86.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other analysts also recently issued reports about the stock. Maxim Group reduced their target price on shares of Semler Scientific from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Friday, September 19th. Cantor Fitzgerald reduced their target price on shares of Semler Scientific from $61.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 6th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Semler Scientific has an average rating of “Buy” and an average price target of $74.25.

Semler Scientific Stock Down 4.5%

NASDAQ:SMLR opened at $30.21 on Tuesday. The firm’s 50-day moving average price is $32.80 and its 200-day moving average price is $35.35. The company has a market capitalization of $447.41 million, a PE ratio of 12.43 and a beta of 1.39. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.60 and a quick ratio of 0.58. Semler Scientific has a 1-year low of $22.22 and a 1-year high of $81.56.

Semler Scientific (NASDAQ:SMLR) last released its earnings results on Monday, August 4th. The company reported $5.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $5.31. The firm had revenue of $8.22 million for the quarter, compared to the consensus estimate of $8.10 million. Semler Scientific had a net margin of 86.20% and a return on equity of 43.84%.

Institutional Trading of Semler Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of the company. SummerHaven Investment Management LLC increased its stake in Semler Scientific by 2.0% during the 2nd quarter. SummerHaven Investment Management LLC now owns 23,570 shares of the company’s stock valued at $913,000 after purchasing an additional 464 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Semler Scientific during the 4th quarter valued at about $30,000. Cambridge Investment Research Advisors Inc. increased its stake in Semler Scientific by 10.2% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,226 shares of the company’s stock valued at $225,000 after purchasing an additional 576 shares in the last quarter. SBI Securities Co. Ltd. increased its stake in Semler Scientific by 161.3% during the 1st quarter. SBI Securities Co. Ltd. now owns 959 shares of the company’s stock valued at $35,000 after purchasing an additional 592 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Semler Scientific by 15.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,582 shares of the company’s stock valued at $178,000 after acquiring an additional 617 shares during the last quarter. 49.37% of the stock is currently owned by institutional investors.

About Semler Scientific

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.